Literature DB >> 12474154

The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review.

Adam S Bartlett1, Ravi Ramadas, Sue Furness, Ed Gane, John L McCall.   

Abstract

Protocol biopsy results in the first few weeks after liver transplantation sometimes display histologic features of acute cellular rejection (ACR), even in the absence of significant clinical or biochemical dysfunction. At present there is no clear consensus about the need to treat such cases with adjuvant immunosuppression. This systematic review describes, from the available evidence, the natural history of untreated histologic ACR in the absence of biochemical graft dysfunction. An electronic search of the Medline, Embase, and Cochrane Library databases was performed to select studies that reported protocol liver biopsies in the early posttransplant period from 1983 to 2000. Studies that identified patients with ACR on protocol biopsy who were not treated with adjuvant immunosuppression formed the basis of the study group. Data from individual studies were extracted using standardized pro forma and pooled for descriptive analysis. The search identified 3431 studies, of which 516 were cited in full. Of these, 15 studies met all of the inclusion criteria. These 15 studies reported on 1566 patients who had protocol biopsies performed in the early posttransplant period, of which 1048 (67%) had histologic evidence of ACR. Three hundred and thirty one (32%) patients with histologic ACR on protocol biopsy had no associated biochemical graft dysfunction. Without treatment, only 14% of these patients subsequently developed biochemical graft dysfunction requiring adjuvant immunosuppression. Steroid-resistant rejection and chronic rejection both had a prevalence of 4% in patients with untreated histologic ACR and no biochemical graft dysfunction. Withholding adjuvant immunosuppression from patients with histologic ACR and no biochemical graft dysfunction seems to be safe, as long as graft function is carefully monitored. The rationale for performing protocol biopsies in the absence of biochemical graft dysfunction is questionable.

Entities:  

Mesh:

Year:  2002        PMID: 12474154     DOI: 10.1053/jlts.2002.36240

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

Review 1.  Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Rinkesh K Bansal; Neeraj Saraf; Dheeraj Gautam; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

2.  Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.

Authors:  Alexandre Loupy; Dewi Vernerey; Claire Tinel; Olivier Aubert; Jean-Paul Duong van Huyen; Marion Rabant; Jérôme Verine; Dominique Nochy; Jean-Philippe Empana; Frank Martinez; Denis Glotz; Xavier Jouven; Christophe Legendre; Carmen Lefaucheur
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

Review 3.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

4.  New Approaches to the Diagnosis of Rejection and Prediction of Tolerance in Liver Transplantation.

Authors:  Timucin Taner; Julia Bruner; Juliet Emamaullee; Eliano Bonaccorsi-Riani; Ali Zarrinpar
Journal:  Transplantation       Date:  2022-05-16       Impact factor: 5.385

5.  The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation.

Authors:  Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

Review 6.  Management of immunosuppressant agents following liver transplantation: Less is more.

Authors:  Mustafa S Ascha; Mona L Ascha; Ibrahim A Hanouneh
Journal:  World J Hepatol       Date:  2016-01-28

7.  The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation.

Authors:  Su Kah Goh; Hongdo Do; Adam Testro; Julie Pavlovic; Angela Vago; Julie Lokan; Robert M Jones; Christopher Christophi; Alexander Dobrovic; Vijayaragavan Muralidharan
Journal:  Transplant Direct       Date:  2019-06-21

8.  Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment.

Authors:  Marko Vannas; Johanna Arola; Arno Nordin; Helena Isoniemi
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

Review 9.  The Immunological Basis of Liver Allograft Rejection.

Authors:  Vincenzo Ronca; Grace Wootton; Chiara Milani; Owen Cain
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

10.  Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies.

Authors:  Safak Gül-Klein; Henriette Hegermann; Robert Röhle; Moritz Schmelzle; Frank Tacke; Wenzel Schöning; Robert Öllinger; Tomasz Dziodzio; Patrick Maier; Julius M Plewe; David Horst; Igor Maximilian Sauer; Johann Pratschke; Nils Lachmann; Dennis Eurich
Journal:  J Inflamm Res       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.